| Date Filed | Type | Description |
| 10/05/2023 |
DEFA14C
| Form DEFA14C - Additional information statement materials, definitive: |
| 10/05/2023 |
DEFA14C
| Form DEFA14C - Additional information statement materials, definitive: |
| 10/05/2023 |
DEFA14C
| Form DEFA14C - Additional information statement materials, definitive: |
| 10/05/2023 |
DEFA14C
| Form DEFA14C - Additional information statement materials, definitive: |
| 10/05/2023 |
DEFA14C
| Form DEFA14C - Additional information statement materials, definitive: |
| 10/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 08/22/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/21/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Investor presentation, Quarterly results |
| 06/16/2023 |
4
| Altschuler Steven (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| Curnutte John T (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| Dunoyer Marc (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| GERAGHTY JAMES A (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| Beck Joanne T. (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| Secor Alicia (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 06/16/2023 |
4
| Rowland Charles A Jr (Director) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Granted 105,000 options to buy
@ $0.495, valued at
$52k
|
|
| 05/23/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"TIME AGENDA TOPIC SPEAKERS 8:00",
"Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatment for autoimmune disorders Company to host conference call and webcast Tuesday, May 23 at 8:00 a.m. EDT BOSTON and LONDON, May 18, 2023, -- Orchard Therapeutics , a global gene therapy leader, today presented new data from the company’s hematopoietic stem cell gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Socie...",
"Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study in MPS-IIIA patients show additional favorable neurocognitive outcomes compared to disease natural history with median follow-up of 2.5 years First preclinical data for OTL-204 highlight ability of HSC gene therapy to restore microglial function, modulate neuroinflammation, and normalize predictive biomarkers in the progranulin form of frontotemporal dementia Company to host co..." |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 03/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/20/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in ORCHARD THERAPEUTICS PLC |
| 03/14/2023 |
4
| THOMAS FRANK E (See Remarks) has filed a Form 4 on Orchard Therapeutics plc|
Txns:
| Exercised 20,000 options to buy
@ $0.4591, valued at
$9.2k
|
|
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
|